Subscribe X
Back to Top


May 16, 2018 by Reuters Staff | Reuters Health News

Depression, Anxiety Worse in Patients With IBS Than Those With IBD

NEW YORK (Reuters Health) – Comorbid symptoms of anxiety and depression are worse in patients with irritable bowel syndrome (IBS) compared to those with inflammatory bowel disease (IBD), a new meta-analysis shows.

“Although the prevalence of depression was similar between IBS and IBD patients, the study found that depression and anxiety was more severe in IBS patients compared to IBD patients,” Dr. Qin Geng of China-Japan Friendship Hospital in Beijing and his colleagues note in the Journal of Affective Disorders, online May 4.

Depression and anxiety occur frequently in people with IBS, IBD and other chronic gastrointestinal disorders, Dr. Geng and colleagues write. “Adequate research on the comorbidity of depression and anxiety in these conditions is necessary to develop appropriate screening, plan treatment strategies and rationalize utilization of health resources,” they add.

They analyzed 22 studies including a total of 2,292 subjects, 1,244 with IBS and 1,048 with IBD. Both depressive symptoms (pooled standardized mean difference, 0.18) and anxiety symptoms (pooled SMD, 0.31) were significantly more severe in the IBS patients than in those with IBD.

There was also a higher prevalence of depression in the IBS patients, but the difference was not statistically significant.

There are several possible explanations for why symptoms of depression and anxiety are worse in IBS than in IBD, the authors note. “IBS is a functional disease that is considered to be greatly influenced by psychological factors, whereas IBD is an organic disease in which comorbid psychiatric problems are often secondary to disease itself,” they write.

Past research has found that people with IBS are more distressed and report having less support regarding their physical symptoms than those with IBD, the authors note.

They conclude: “Appropriate assessment and treatment of depressive and anxiety symptoms in these patient groups should be implemented.”

SOURCE: J Affect Disord 2018.



Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Related Blogs

  • Dr. David Healy

    Dr. David Healy

    Dr. Healy is a professor of psychiatry at Cardiff University in Wales and an author on the history of pharmaceuticals and government regulation.
  • Mad In America: Robert Whitaker

    Mad In America: Robert Whitaker

    Journalist and author Bob Whitaker distills the latest in pharmaceutical and mental health research.
  • Selling Sickness

    Selling Sickness

    Creating a new partnership movement to challenge the selling of sickness.
  • Kathy Brous

    Kathy Brous

    A serial of Kathy's recovery journey as an adult with attachment disorder.
  • Nev Jones

    Nev Jones

    Exploring the intersections of psychiatry, philosophy, neuroscience, cultural theory, critical community psychology and the mad/user/survivor movement.
  • 1boringoldman


    Retired psychiatrist and raconteur offers insightful analysis of the day's events from the woods of Georgia.